| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/23/2003 | EP0625910B1 Dual carrier immunogenic construct |
| 07/23/2003 | CN1432063A Humanised antibodies to epidermal growth factor receptor |
| 07/23/2003 | CN1432024A Immunodominant acetylcholine receptor alpha subunit peptides |
| 07/23/2003 | CN1431913A Vaccine compsn. |
| 07/23/2003 | CN1431907A Method of treating hepatitis delta viral infection |
| 07/23/2003 | CN1431864A Vaccines, immunotherapeutics and methods for using same |
| 07/23/2003 | CN1431311A Method for expressing thymopolypeptides šŒ1 by use of escherichia coli and its application |
| 07/23/2003 | CN1431305A Reorganization immunity toxin with high specificity and its preparing method |
| 07/23/2003 | CN1431020A Epiposition vaccine of gene engineering for influenza virus and its preparing method |
| 07/23/2003 | CN1431017A Microcapsule meterial for durative releasing two factors for restraining new-born blood vessels and its preparing method |
| 07/22/2003 | USRE38202 Antibodies specific for a haemostatic protein, their use for isolating protein, haemostatic compositions devoid of proteolytic cleavage products of the protein |
| 07/22/2003 | US6596861 Subjecting reaction mixture comprising a bacterial polysaccharide, an amino compound and a reducing agent to microwave radiation; useful in conjugating polysaccharides to polypeptides and vaccine development |
| 07/22/2003 | US6596539 Modification of virus tropism and host range by viral genome shuffling |
| 07/22/2003 | US6596529 Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof |
| 07/22/2003 | US6596283 Chemically-modified group B polysaccharides of Neisseria meningitidis for use as vaccines |
| 07/22/2003 | US6596282 Treatment of chronic viral infections with M. vaccae |
| 07/22/2003 | US6596280 Live bimavirus such as infectious bursal disease virus |
| 07/22/2003 | US6596279 Immunodeficiency recombinant poxvirus |
| 07/22/2003 | US6596278 Immunological response potentiation process |
| 07/22/2003 | US6596275 Increasing release of PGE-2, IL-10 and/or IL-4; decreasing expression and secretion of IL-1, IL-12 and/or IFM gamma cytokines; decreasing prescence of CD80, CD86 and/or CD40 antigens; having polylysine-cDNA encoding cell nucleus |
| 07/22/2003 | US6596270 Administering the adenoviral gene transfer vector (exogenous) encoding a gene product to a muscle and the vector is neutralized outside of the muscle by systemic neutralizing antibodies; using a chimeric coat protein for cell entry |
| 07/22/2003 | US6596268 Viruses for the treatment of cellular proliferative disorders |
| 07/22/2003 | CA2033085C Use of vaccine preparations containing adenyl cyclase or adenyl cyclase producing bacteria as protecting antigens against bordetella effects |
| 07/17/2003 | WO2003058248A2 Diagnostics and vaccines for mycrobacterium paratuberculosis infections |
| 07/17/2003 | WO2003057926A1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/17/2003 | WO2003057885A1 Hiv-1 virus tat-protein mutants |
| 07/17/2003 | WO2003057881A1 Method of stabilizing protein |
| 07/17/2003 | WO2003057867A2 Regulation of human fatty acid coa ligase-like amp-binding enzyme |
| 07/17/2003 | WO2003057854A2 Novel proteins and nucleic acids encoding same |
| 07/17/2003 | WO2003057852A2 Purification and characterization of hla proteins |
| 07/17/2003 | WO2003057842A2 Aggrecanase molecules |
| 07/17/2003 | WO2003057838A2 Antibodies against the muc18 antigen |
| 07/17/2003 | WO2003057837A2 Methods for using anti-muc18 antibodies |
| 07/17/2003 | WO2003057834A2 Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines |
| 07/17/2003 | WO2003057829A2 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 07/17/2003 | WO2003057824A2 Compositions and methods for the inhibition of membrane fusion by paramyxoviruses |
| 07/17/2003 | WO2003057823A2 Epitope synchronization in antigen presenting cells |
| 07/17/2003 | WO2003057822A2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 07/17/2003 | WO2003057733A1 Antibodies against fibroblast growth factor 23 |
| 07/17/2003 | WO2003057714A2 A method of developing an anti-protein and regulation of a cellular function by administering an effective amount of the anti-protein |
| 07/17/2003 | WO2003057252A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | WO2003057250A1 Cancer treatment |
| 07/17/2003 | WO2003057249A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 07/17/2003 | WO2003057239A1 Polyphenol inhibition of nucleoside diphosphate kinase-b activity and cancer metastasis |
| 07/17/2003 | WO2003057168A2 Cancer-associated epitope |
| 07/17/2003 | WO2003057163A2 Methods for preparing immunoconjugates |
| 07/17/2003 | WO2003057160A2 Compositions and methods for the diagnosis and treatment of tumor |
| 07/17/2003 | WO2003057159A2 Psoriasin expression by breast epithelial cells |
| 07/17/2003 | WO2003057155A2 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| 07/17/2003 | WO2003057148A2 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/17/2003 | WO2003057146A2 Novel compositions and methods for cancer |
| 07/17/2003 | WO2003057130A2 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 07/17/2003 | WO2003057006A2 Use of antibodies against the muc18 antigen |
| 07/17/2003 | WO2003038057A3 Genetic vaccine against human immunodeficiency virus |
| 07/17/2003 | WO2003031595A3 Molecules for disease detection and treatment |
| 07/17/2003 | WO2003020371A3 Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer |
| 07/17/2003 | WO2003011329A3 Vaccine for prophylaxis and therapy of dermatophytosis in veterinary and human medicine |
| 07/17/2003 | WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 07/17/2003 | WO2002099044A3 B3galts as modifiers of the p53 pathway and methods of use |
| 07/17/2003 | WO2002090566A3 Recombinant tumor specific antibody and use thereof |
| 07/17/2003 | WO2002083928A3 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
| 07/17/2003 | WO2002081646A3 Epitope sequences |
| 07/17/2003 | WO2002074335A3 Equine herpesvirus vaccine |
| 07/17/2003 | WO2002072008A3 Method for treating cancer using a33 specific antibodies and chemotherapeutic agents |
| 07/17/2003 | WO2002066057A3 Methods and compositions for preventing and treating neutrophil-mediated diseases |
| 07/17/2003 | WO2002059286A3 Adenylate cyclases |
| 07/17/2003 | WO2002038803A3 Novel marker for the diagnosis and therapy of tumours |
| 07/17/2003 | WO2002029060A9 Hematopoietin receptors hpr1 and hpr2 |
| 07/17/2003 | WO2002022805A3 Modulation of il-2- and il-15-mediated t cell responses |
| 07/17/2003 | WO2002011759A9 Vaccines against cytokines and growth factors derived from malignant tumours |
| 07/17/2003 | WO2001064869A9 Tumor-related antigen |
| 07/17/2003 | US20030135037 Plasmid comprising chimeric paracrystalline surface layer protein fused to infectious hematopoietic necrosis virial proteins; nonpathogenic gene transfer vechile |
| 07/17/2003 | US20030135034 Nucleotide sequences coding extracellular membrane proteins; antitumor agents; antiproliferative agents; antiiiflammatory agents; enterotoxins; neuroprotectants |
| 07/17/2003 | US20030135026 Compounds and methods for diagnosis of tuberculosis |
| 07/17/2003 | US20030134826 Cell surface binding group or a cell recognising group, and also by a bio-active group, the bio- active group attached to a carbonyl of the cross-linker by an acid labile bond. Examples of suitable bio-active groups including |
| 07/17/2003 | US20030134814 Isolated nucleic acids molecules, designated 18080 nucleic acid molecules, which encode serine carboxypeptidase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18080 nucleic acid |
| 07/17/2003 | US20030134787 Engineered to noncovalently bind to heat shock proteins; (ii) to compositions comprising such conjugate peptides, optionally bound to heat shock protein; and (iii) to methods of using such compositions to induce an immune response in a subject in |
| 07/17/2003 | US20030134785 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 07/17/2003 | US20030134784 A novel gene (designated 83P2H3) and its encoded protein are described. While 83P2H3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in prostate cancer. 83P2H3 provides a diagnostic and/or theraputic target |
| 07/17/2003 | US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides |
| 07/17/2003 | US20030134419 Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| 07/17/2003 | US20030134415 Producing polyclonal autologous t-cells in the absence of exogenous cytokines; antiinflammatory agents; antitumor agents |
| 07/17/2003 | US20030134407 Nucleic acids and proteins from Streptococcus pneumoniae |
| 07/17/2003 | US20030134387 Vertebrate globin |
| 07/17/2003 | US20030134344 Her2 gene amplification as detected by fluorescence in situ hybridization |
| 07/17/2003 | US20030134341 Th1 cell adoptive immunotherapy |
| 07/17/2003 | US20030134335 Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes |
| 07/17/2003 | US20030134314 Assaying the ability of specific polypeptide activity, thereby identifying a compound capable of treating a hematologic disorder |
| 07/17/2003 | US20030133988 Immunomodulation accomplished by administration of immunomodulatory polynucleotide/microcarrier complexes comprising 3-6 mer immunomodulatory oligonucleotides |
| 07/17/2003 | US20030133953 Complexing a biologically active agent with a perturbant to reversibly transform and exposing a membrane or bilayer to the supramolecular complex |
| 07/17/2003 | US20030133952 D-alanine racemase mutants of mycobacteria and uses therefore |
| 07/17/2003 | US20030133950 Inducing a desired T helper lymphocyte regulated immune response by delivering an immunogen to a preselected region of the gastrointestinal tract of a patient |
| 07/17/2003 | US20030133947 Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies |
| 07/17/2003 | US20030133944 Vaccine composition against malaria |
| 07/17/2003 | US20030133943 Protective recombinant Haemophilus influenzae high molecular weight proteins |
| 07/17/2003 | US20030133942 Vaccine compositions and methods of modulating immune responses |
| 07/17/2003 | US20030133941 Method of separating protective components of bordetella pertussis |
| 07/17/2003 | US20030133938 Antibody-avidin fusion proteins as cytotoxic drugs |
| 07/17/2003 | US20030133934 Method for enhancing the presentation of exogenous antigen by human antigen-presenting cells and opsonized micro particle complexes for applying this method |
| 07/17/2003 | US20030133933 Novel integrin alpha subunit |